The pharmacodynamic effects of a lower-lipid emulsion of propofol: A comparison with the standard propofol emulsion

被引:31
作者
Song, DJ [1 ]
Hamza, M [1 ]
White, PF [1 ]
Klein, K [1 ]
Recart, A [1 ]
Khodaparast, O [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA
关键词
D O I
10.1213/01.ANE.0000103184.36451.D7
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Using a randomized, double-blind protocol design, we compared a new lower-lipid emulsion of propofol (Ampofol((R))) containing propofol 1%, soybean oil 5%, and egg lecithin 0.6% with the most commonly used formulation of propofol (Diprivan((R))) with respect to onset of action and recovery profiles, as well as intraoperative efficacy, when administered for induction and maintenance of general anesthesia as part of a "balanced" anesthetic technique in 63 healthy outpatients. Anesthesia was induced with sufentanil 0.1 mug/kg (or fentanyl 1 mug/kg) and propofol 2 mg/kg IV and maintained with a variable-rate propofol infusion, 120-200 mug (.) kg(-1) (.) min(-1). Onset times to loss of the eyelash reflex and dropping a syringe were recorded. Severity of pain on injection, speed of induction, intraoperative hemodynamic variables, and electroencephalographic bispectral index values were assessed. Recovery times to opening eyes and orientation were noted. The results demonstrated that there were no significant differences between Ampofol((R)) and Diprivan((R)) with respect to onset times, speed of induction, anesthetic dose requirements, bispectral index values, hemodynamic variables, recovery variables, or patient satisfaction. However, the incidence of pain on injection was more frequent in the Ampofol((R)) group (26% versus 6%, P < 0.05). We conclude that Ampofol((R)) is equipotent to Diprivan((R)) with respect to its anesthetic properties but was associated with a more frequent incidence of mild pain on injection.
引用
收藏
页码:687 / 691
页数:5
相关论文
共 12 条
[1]   Reducing pain during propofol injection: The role of the solvent [J].
Doenicke, AW ;
Roizen, MF ;
Rau, J ;
Kellermann, W ;
Babl, J .
ANESTHESIA AND ANALGESIA, 1996, 82 (03) :472-474
[2]   LIPID DEPOSITION DURING THE LONG-TERM INFUSION OF PROPOFOL [J].
ELEBIARY, M ;
TORRES, A ;
RAMIREZ, J ;
XAUBET, A ;
RODRIGUEZROISIN, R .
CRITICAL CARE MEDICINE, 1995, 23 (11) :1928-1930
[3]   PROPOFOL - AN OVERVIEW OF ITS PHARMACOLOGY AND A REVIEW OF ITS CLINICAL EFFICACY IN INTENSIVE-CARE SEDATION [J].
FULTON, B ;
SORKIN, EM .
DRUGS, 1995, 50 (04) :636-657
[4]  
RABINOWITZ JL, 1978, AM J GASTROENTEROL, V69, P187
[5]   Propofol in an emulsion of long- and medium-chain triglycerides: The effect on pain [J].
Rau, J ;
Roizen, MF ;
Doenicke, AW ;
O'Connor, MF ;
Strohschneider, U .
ANESTHESIA AND ANALGESIA, 2001, 93 (02) :382-384
[6]   Pharmaceutical and antimicrobial differences between propofol emulsion products [J].
Redhead, HM ;
Jones, CB ;
Bobey, DG .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (12) :1174-+
[7]   Bisulfite-containing propofol:: Is it a cost-effective alternative to Diprivan™ for induction of anesthesia? [J].
Shao, XL ;
Li, H ;
White, PF ;
Klein, KW ;
Kulstad, C ;
Owens, A .
ANESTHESIA AND ANALGESIA, 2000, 91 (04) :871-875
[8]  
Sklar GE, 1997, ANN PHARMACOTHER, V31, P1521
[9]  
SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
[10]   Propofol in a medium- and long-chain triglyceride emulsion: Pharmacological characteristics and potential beneficial effects [J].
Theilen, HJ ;
Adam, S ;
Albrecht, MD ;
Ragaller, M .
ANESTHESIA AND ANALGESIA, 2002, 95 (04) :923-929